Heigener, D: search on Z-Library

The world's largest scientific articles store. 70,000,000+ articles for free.

1

Long-Term Safety and Tolerability of Sorafenib in Patients with Advanced Non–Small-Cell Lung Cancer: A Case-Based Review

Alex A. Adjei, George R. Blumenschein Jr., Sumithra Mandrekar, Shauna Hillman, Ulrich Gatzemeier, David Heigener

Journal:

Clinical Lung Cancer

Year:

2011

Language:

english

File:

PDF, 307 KB

english, 2011

2

Book Review - Lung Cancer Therapy Annual 6, Sixth Edition

Heigener, David F

Journal:

Year:

2009

Language:

english

File:

PDF, 203 KB

english, 2009

3

Diagnosis of Malignant Mesothelioma: A Clinical and Pathological Challenge

Kanappilly, Antony, Rabe, Klaus Friedrich, Heigener, David Felix, Stellmacher, Florian, Welker, Lutz

Journal:

Year:

2014

Language:

english

File:

PDF, 18 KB

english, 2014

4

Stadieneinteilung des nichtkleinzelligen Lungenkarzinoms

D.F. Heigener, K.-M. Deppermann, M. Sebastian, M. Reck

Journal:

Year:

2011

Language:

german

File:

PDF, 353 KB

german, 2011

5

The gefitinib long-term responder (LTR)—A cancer stem-like cell story? Insights from molecular analyses of German long-term responders treated in the IRESSA expanded access program (EAP)

Gottschling, Sandra, Herpel, Esther, Eberhardt, Wilfried E.E., Heigener, David F., Fischer, Jürgen R., Köhne, Claus-Henning, Kortsik, Cornelius, Kuhnt, Thomas, Muley, Thomas, Meister, Michael, Bischof

Journal:

Year:

2012

Language:

english

File:

PDF, 1.15 MB

english, 2012

6

Nicht-kleinzelliges Lungenkarzinom: Neues aus der Immuntherapie

N. Reinmuth, D. Heigener, M. Reck

Year:

2015

Language:

german

File:

PDF, 245 KB

german, 2015

7

Immunotherapy: the third wave in lung cancer treatment

Heigener, David Felix, Reck, Martin

Journal:

The Lancet Respiratory Medicine

Year:

2015

Language:

english

File:

PDF, 365 KB

english, 2015

8

Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 Study

Gottfried, Maya, Bennouna, Jaafar, Bondarenko, Igor, Douillard, Jean-Yves, Heigener, David F., Krzakowski, Maciej, Mellemgaard, Anders, Novello, Silvia, Orlov, Sergei, Summers, Yvonne, von Pawel, Joac

Journal:

Targeted Oncology

Year:

2017

Language:

english

File:

PDF, 1.75 MB

english, 2017

9

PCN87 A COST-EFFECTIVENESS ANALYSIS OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) COMPARED WITH PEMETREXED PLUS CISPLATIN (PC) FOR THE TREATMENT OF ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY

HG Bischoff, D Heigener, C Wiesner, S Walzer

Journal:

Value in Health

Year:

2009

Language:

english

File:

PDF, 72 KB

english, 2009

10

Second-line erlotinib in patients with advanced non-small-cell lung cancer: Subgroup analyses from the TRUST study

Heigener, David F., Wu, Yi-Long, van Zandwijk, Nico, Mali, Pekka, Horwood, Keith, Reck, Martin

Journal:

Year:

2011

Language:

english

File:

PDF, 347 KB

english, 2011

11

Frühe palliative Intervention

Eschbach, Corinna, Heigener, David, Nehls, Wiebke, Villalobos, Matthias, van Oorschot, Birgitt

Journal:

Wiener Klinisches Magazin

Year:

2015

Language:

german

File:

PDF, 242 KB

german, 2015

12

Behandlung des nichtkleinzelligen Lungenkarzinoms; Treatment of non-small cell lung cancer;

Heigener, David F., Schiller, Johanna, Reck, Martin

Journal:

Year:

2018

Language:

german

File:

PDF, 650 KB

german, 2018

13

Behandlung des nichtkleinzelligen Lungenkarzinoms

N. Reinmuth, D. Heigener, M. Reck

Journal:

Year:

2011

Language:

german

File:

PDF, 584 KB

german, 2011

14

PCN82 COST COMPARISON OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE VERSUS PEMETREXED AND CISPLATIN THERAPY IN PATIENTS WITH ADVANCED OR RECURRENT NON-SQUAMOUS NON-SMALL CELL CANCER IN GERMANY – AN UPDATED ANALYSIS

HG Bischoff, A Hermes, DF Heigener, S Cesaro-Tadic, S Walzer, M Nuijten

Journal:

Value in Health

Year:

2010

Language:

english

File:

PDF, 70 KB

english, 2010

15

Reduzierte Dosis von TKI führt nicht zu Wirkungsverlust bei Patienten mit aktivierender EGFR-Mutation

Reinmuth, N., Heigener, D., Goldmann, T., Watermann, I., Reck, M.

Journal:

Year:

2014

File:

PDF, 342 KB

2014

16

Empfehlung der Sektionen 2 und 11 der DGP zur Rebiopsie bei Lungenkarzinomen

Brückl, W., Ficker, J., Tiemann, M., Schumann, C., Reinmuth, N., Heigener, D., Schütte, W., Eberhardt, R., Darwiche, K., Wagner, M.

Journal:

Year:

2018

Language:

german

File:

PDF, 474 KB

german, 2018

17

Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe

Rosery, Hubertus, Walleser,, Ray,, Bischoff,, Vergnenègre, Alain, Rosery, Hubertus, Chouaid, Christos, Heigener,, de Castro,, Tiseo, Marcello, Walzer, Stefan

Journal:

ClinicoEconomics and Outcomes Research

Year:

2012

Language:

english

File:

PDF, 327 KB

english, 2012

18

Open, randomized, multi-center phase II study comparing efficacy and tolerability of Erlotinib vs. Carboplatin/Vinorelbin in elderly patients (>70 years of age) with untreated non-small cell lung cancer

Heigener, D.F., Deppermann, K.M., Pawel, J.v., Fischer, J.R., Kortsik, C., Bohnet, S., Eiff, M.v., Koester, W., Thomas, M., Schnabel, P.A., Reck, M.

Journal:

Year:

2014

Language:

english

File:

PDF, 518 KB

english, 2014

19

PCN14 AN INDIRECT COMPARISON OF THE EFFICACY OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) OR BEVACIZUMAB PLUS CARBOPLATIN AND PACLITAXEL (BCP) VERSUS CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)

S Walzer, J de Castro Carpeño, A Vergnenegre, C Chouaid, D Heigener, HG Bischoff, R Aultman, U Siebert

Journal:

Value in Health

Year:

2009

Language:

english

File:

PDF, 80 KB

english, 2009

20

Was sollte der Pneumologe über Palliativmedizin wissen?

Nehls, W., Heigener, D. F.

Journal:

Year:

2016

Language:

german

File:

PDF, 387 KB

german, 2016

21

Immuntherapie des Lungenkarzinoms

Heigener, D. F., Steffen, P., Reck, M.

Journal:

Year:

2016

Language:

german

File:

PDF, 291 KB

german, 2016

22

Efficacy and safety of nintedanib (NIN)/docetaxel (DOC) in patients with lung adenocarcinoma: Further analyses from the LUME-Lung 1 study

Heigener, D., Gottfried, M., Bennouna, J., Bondarenko, I., Douillard, J-Y., Krzakowski, M., Mellemgaard, A., Novello, S., Orlov, S., Summers, Y.J., von Pawel, J., Hocke, J., Kaiser, R., Reck, M.

Journal:

Annals of Oncology

Year:

2016

Language:

english

File:

PDF, 42 KB

english, 2016

23

PCN41 COST-SAVINGS ASSOCIATED WITH BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) COMPARED WITH CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY

D Heigener, HG Bischoff, C Wiesner, R Aultman

Journal:

Value in Health

Year:

2009

Language:

english

File:

PDF, 92 KB

english, 2009

24

Response to Letter to the Editor

Bischoff, Helge G., Heigener, David F., Walzer, Stefan, Nuijten, Mark

Journal:

Year:

2011

Language:

english

File:

PDF, 46 KB

english, 2011

25

Impact of PD-L1 Expression in EGFR -Positive NSCLC? The Answer Remains the Same…

Heigener, David F., Reck, Martin

Journal:

Journal of Thoracic Oncology

Year:

2018

Language:

english

File:

PDF, 138 KB

english, 2018

26

Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Gemcitabine/Cisplatin Alone or With Sorafenib for the First-Line Treatment of Advanced, Nonsquamous Non-Small-Cell Lung Cancer

Paz-Ares, L. G., Biesma, B., Heigener, D., von Pawel, J., Eisen, T., Bennouna, J., Zhang, L., Liao, M., Sun, Y., Gans, S., Syrigos, K., Le Marie, E., Gottfried, M., Vansteenkiste, J., Alberola, V., St

Journal:

Journal of Clinical Oncology

Year:

2012

Language:

english

File:

PDF, 163 KB

english, 2012

27

PCN67 LOWER ADMINISTRATION COSTS OF BEVACIZUMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY VERSUS CETUXIMAB-VINORELBINE-CISPLATIN THERAPY FOR THE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER (MNSCLC) FOCUSING ON THREE EUROPEAN HEALTH CARE SYSTEMS

H Rosery, C Castro de, H Bischoff, D Heigener, A Vergnenegre, C Chouaid, S Walzer

Journal:

Value in Health

Year:

2009

Language:

english

File:

PDF, 71 KB

english, 2009

28

Prospective, multicenter, randomized, independent-group, open-label phase II study to investigate the efficacy and safety of three regimens with two doses of sagopilone as second-line therapy in patients with stage IIIB or IV non-small-cell lung cancer

Heigener, David F., von Pawel, Joachim, Eschbach, Corinna, Brune, Andreas, Schmittel, Alexander, Schmelter, Thomas, Reck, Martin, Fischer, Jürgen R.

Journal:

Year:

2013

Language:

english

File:

PDF, 316 KB

english, 2013

29

Weekly and every 2 weeks cetuximab maintenance therapy after platinum-based chemotherapy plus cetuximab as first-line treatment for non-small cell lung cancer: randomized non-comparative phase IIIb NEXT trial

Heigener, David F., Pereira, José Rodrigues, Felip, Enriqueta, Mazal, Juraj, Manzyuk, Lyudmila, Tan, Eng Huat, Merimsky, Ofer, Sarholz, Barbara, Esser, Regina, Gatzemeier, Ulrich

Journal:

Targeted Oncology

Year:

2015

Language:

english

File:

PDF, 365 KB

english, 2015

30

Nicht-kleinzelliges Lungenkarzinom: Neues aus der Immuntherapie

Reinmuth, N., Heigener, D., Reck, M.

Journal:

TumorDiagnostik & Therapie

Year:

2015

Language:

german

File:

PDF, 189 KB

german, 2015

31

Okkulte Fremdkörperaspiration als Differentialdiagnose zum Bronchialka

David Heigener, Peter Lotz, Reyhan Akkan, Jan Fraedrich, Lutz Welker, Ulrich Gatzemeier

Journal:

Medizinische Klinik - Intensivmedizin und Notfallmedizin

Year:

2007

Language:

german

File:

PDF, 200 KB

german, 2007

32

Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer: Impact on treatment beyond gefitinib and erlotinib

David F. Heigener, Martin Reck

Journal:

Advances in Therapy

Year:

2011

Language:

english

File:

PDF, 180 KB

english, 2011

33

Feed Additive, Nitrofurazone Determination in Poultry Feed by Phenylhydrazine or Alkali Reaction

Brüggemann, Johannes, Bronsch, Kurt, Heigener, Herbert, Knapstein, Hans

Journal:

Journal of Agricultural and Food Chemistry

Year:

1962

Language:

english

File:

PDF, 494 KB

english, 1962

34

Nicht-kleinzelliges Lungenkarzinom: Neues aus der Immuntherapie

Reinmuth, N., Heigener, D., Reck, M.

Journal:

TumorDiagnostik & Therapie

Year:

2016

Language:

german

File:

PDF, 189 KB

german, 2016

35

Efficacy and safety of bronchoscopic laser therapy in patients with tracheal and bronchial obstruction: a retrospective single institution report

Andreas Hermes, David Heigener, Ulrich Gatzemeier, Joachim Schatz, Martin Reck

Journal:

The Clinical Respiratory Journal

Year:

2012

Language:

english

File:

PDF, 459 KB

english, 2012

36

9164 An indirect comparison of the efficacy of bevacizumab plus cisplatin and gemcitabine (BCG) or bevacizumab plus carboplatin and paclitaxel (BCP) versus pemetrexed plus cisplatin (PC) and cetuximab plus vinorelbine and cisplatin (CVC) in patients (pts) with advanced or recurrent non-small cell cancer (NSCLC)

Walzer, S., de Castro Carpeno, J., Vergnenegre, A.V., Chouaid, C., Heigener, D.F.H., Bischoff, H.G., Nicolson, M.C., Aultman, R., Siebert, U.

Journal:

European Journal of Cancer Supplements

Year:

2009

Language:

english

File:

PDF, 48 KB

english, 2009

37

Palliative Care Concepts in Respiratory Disease

Heigener, D.F., Rabe, K.F.

Journal:

Year:

2011

Language:

english

File:

PDF, 157 KB

english, 2011

38

Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors

Heigener, D. F., Schumann, C., Sebastian, M., Sadjadian, P., Stehle, I., Marten, A., Luers, A., Griesinger, F., Scheffler, M.

Journal:

Year:

2015

Language:

english

File:

PDF, 813 KB

english, 2015

39

Topotecan/Cisplatin Compared with Cisplatin/Etoposide as First-Line Treatment for Patients with Extensive Disease Small-Cell Lung Cancer: Final Results of a Randomized Phase III Trial

Fink, Thomas H., Huber, Rudolf M., Heigener, David F., Eschbach, Corrina, Waller, Cornelius, Steinhauer, Ernst U., Virchow, Johann C., Eberhardt, Frank, Schweisfurth, Hans, Schroeder, Michael, Ittel,

Journal:

Journal of Thoracic Oncology

Year:

2012

Language:

english

File:

PDF, 1.14 MB

english, 2012

40

Comparison of PD-L1 expression between paired cytologic and histologic specimens from non-small cell lung cancer patients

Kuempers, C., van der Linde, L. I. S., Reischl, M., Vogel, W., Stellmacher, F., Reck, M., Heigener, D., Rabe, K. F., Kirfel, J., Perner, S., Welker, L.

Journal:

Virchows Archiv

Year:

2019

Language:

english

File:

PDF, 814 KB

english, 2019

41

PCN7 COMPARATIVE EFFECTIVENESS ASSESSMENT OF ERLOTINIB VERSUS GEFITINIB IN FIRST-LINE EGFR ACTIVATING MUTATION POSITIVE NON-SMALL CELL LUNG CANCER

B. Schwander, J. de Castro Carpeño, D.F. Heigener, E. Wright, H.G. Bischoff, S. Walzer

Journal:

Value in Health

Year:

2011

Language:

english

File:

PDF, 55 KB

english, 2011

42

Reviewing the safety of erlotinib in non-small cell lung cancer

Reck, Martin, Mok, Tony, Wolf, Jürgen, Heigener, David, Wu, Yi-long

Journal:

Expert Opinion on Drug Safety

Year:

2011

Language:

english

File:

PDF, 383 KB

english, 2011

43

Palliativmedizin in der Pneumologie oder Pneumologie in der Palliativmedizin - eine Stellungnahme

Heigener, D, Bausewein, C, Karg, O, Rosseau, S, Simon, S, Thomas, M, Magnussen, H

Journal:

DMW - Deutsche Medizinische Wochenschrift

Year:

2011

Language:

german

File:

PDF, 141 KB

german, 2011

44

Die Lauenburgische Sprachlandschaftby Heinrich Scheele

Review by: Hans Heigener

Journal:

Zeitschrift für Mundartforschung

Year:

1938

Language:

german

File:

PDF, 303 KB

german, 1938

45

PCN46 COST SAVINGS RELATED TO SUPERIOR ADVERSE EVENT PROFILE OF BEVACIZUMAB PLUS CHEMOTHERAPY VERSUS CETUXIMAB PLUS CISPLATIN/VINORELBINE IN THE FIRST-LINE THERAPY OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY: A SENSITIVITY ANALYSIS ON THE ECOG STATUS

D Heigener, HG Bischoff, K Banz, S Walzer

Journal:

Value in Health

Year:

2009

Language:

english

File:

PDF, 73 KB

english, 2009

46

PCN8 REAL LIFE OUTCOMES IN 1ST LINE NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC): A PILOT STUDY IN FRANCE AND GERMANY ANALYSING BEVACIZUMAB-BASED VERSUS NON-BEVACIZUMAB-BASED TREATMENTS

H.G. Bischoff, C. Chouaid, A. Vergnenegre, D.F. Heigener, G. Taylor-Stokes, A. Roughley, S. Walzer

Journal:

Value in Health

Year:

2011

Language:

english

File:

PDF, 58 KB

english, 2011

47

Die medikamentöse Therapie des metastasierten nicht-kleinzelligen Lungenkarzinoms

Heigener, D. F., Reinmuth, N., Reck, M.

Journal:

Year:

2016

Language:

german

File:

PDF, 665 KB

german, 2016

48

Lungenkarzinom; Lung cancer;

Heigener, D. F., Reck, M.

Journal:

Year:

2017

Language:

german

File:

PDF, 241 KB

german, 2017

49

Lung cancer in 2017: Giant steps and stumbling blocks

Heigener, David F., Reck, Martin

Journal:

Nature Reviews Clinical Oncology (formerly Nature Clinical Practice Oncology)

Year:

2017

Language:

english

File:

PDF, 161 KB

english, 2017

50

PCN47 COSTS OF TREATING SEVERE ADVERSE EVENTS OBSERVED WITH A REGIMEN OF BEVACIZUMAB PLUS CHEMOTHERAPY VERSUS CETUXIMAB PLUS CISPLATIN/VINORELBINE IN THE FIRST-LINE THERAPY OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY

HG Bischoff, D Heigener, K Banz, S Walzer

Journal:

Value in Health

Year:

2009

Language:

english

File:

PDF, 73 KB

english, 2009

To build up a library is to create a life. It’s never just a random collection of books.

— Carlos María Domínguez

Official channel

Z-Library Desktop Launcher

Z-Library Since 2009 support@1delivery.pm

EnglishРусскийEspañolItalianoελληνικάاللغة العربيةBahasa IndonesiaBahasa Malaysiaहिन्दीDeutschFrançaisPortuguêsУкраїнськаPolski中文繁體中文日本語Tiếng ViệtAzərbaycan DiliՀայոց լեզուภาษาไทยTürk Diliქართველიবাংলাپښتوతెలుగుاردو한국어SrpskiБългарски